Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Tg Therapeutics (TGTX) Operating Income (2016 - 2025)

Historic Operating Income for Tg Therapeutics (TGTX) over the last 10 years, with Q3 2025 value amounting to $29.4 million.

  • Tg Therapeutics' Operating Income rose 13616.7% to $29.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $102.8 million, marking a year-over-year increase of 2045227.72%. This contributed to the annual value of $41.9 million for FY2024, which is 10321.33% up from last year.
  • As of Q3 2025, Tg Therapeutics' Operating Income stood at $29.4 million, which was up 13616.7% from $34.8 million recorded in Q2 2025.
  • Tg Therapeutics' 5-year Operating Income high stood at $114.8 million for Q3 2023, and its period low was -$92.9 million during Q4 2021.
  • Moreover, its 5-year median value for Operating Income was -$35.0 million (2022), whereas its average is -$22.5 million.
  • Per our database at Business Quant, Tg Therapeutics' Operating Income soared by 42830.13% in 2023 and then crashed by 8916.75% in 2024.
  • Quarter analysis of 5 years shows Tg Therapeutics' Operating Income stood at -$92.9 million in 2021, then grew by 16.58% to -$77.5 million in 2022, then skyrocketed by 83.9% to -$12.5 million in 2023, then soared by 339.88% to $29.9 million in 2024, then dropped by 1.95% to $29.4 million in 2025.
  • Its last three reported values are $29.4 million in Q3 2025, $34.8 million for Q2 2025, and $8.6 million during Q1 2025.